Literature DB >> 11357990

Rocky Mountain spotted fever in the United States, 1993-1996.

T A Treadwell1, R C Holman, M J Clarke, J W Krebs, C D Paddock, J E Childs.   

Abstract

During 1993 through 1996, 2,313 cases of Rocky Mountain spotted fever (RMSF) were reported to the Centers for Disease Control and Prevention (CDC) by 42 states and the District of Columbia through the National Electronic Telecommunications System for Surveillance (NETSS). During this same interval, 1,752 case report forms (CRFs) were submitted to CDC and 1,253 (70%) of the cases were categorized as confirmed RMSF by laboratory testing. On the basis of analyses performed with NETSS data, the average annual RMSF incidence during 1993-1996 was 2.2 cases per million persons; the incidence rose from 1.8 in 1993 to 3.3 per million persons in 1996. Incidence for confirmed cases was highest among children 5-9 years of age (3.7 per million) and lowest among individuals older than 70 years of age (1.4 per million). The south Atlantic region accounted for the largest proportion of confirmed cases (52%). The case-fatality rate was highest among persons 70 years of age and older (9.0%) and lowest among adults 40-49 years of age (0.6%).

Entities:  

Mesh:

Year:  2000        PMID: 11357990     DOI: 10.4269/ajtmh.2000.63.21

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  21 in total

Review 1.  Host, pathogen and treatment-related prognostic factors in rickettsioses.

Authors:  E Botelho-Nevers; D Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-26       Impact factor: 3.267

2.  Rocky mountain spotted fever in the United States, 2000-2007: interpreting contemporary increases in incidence.

Authors:  John J Openshaw; David L Swerdlow; John W Krebs; Robert C Holman; Eric Mandel; Alexis Harvey; Dana Haberling; Robert F Massung; Jennifer H McQuiston
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

3.  Absence of Rickettsia rickettsii and occurrence of other spotted fever group rickettsiae in ticks from Tennessee.

Authors:  Abelardo C Moncayo; Sara B Cohen; Charissa M Fritzen; Eileen Huang; Michael J Yabsley; James D Freye; Brett G Dunlap; Junjun Huang; Daniel G Mead; Timothy F Jones; John R Dunn
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

4.  Comparison of the Babesia duncani (WA1) IgG detection rates among clinical sera submitted to a reference laboratory for WA1 IgG testing and blood donor specimens from diverse geographic areas of the United States.

Authors:  Harry E Prince; Mary Lapé-Nixon; Hemlata Patel; Cindy Yeh
Journal:  Clin Vaccine Immunol       Date:  2010-09-22

5.  Trends in clinical diagnoses of Rocky Mountain spotted fever among American Indians, 2001-2008.

Authors:  Arianne M Folkema; Robert C Holman; Jennifer H McQuiston; James E Cheek
Journal:  Am J Trop Med Hyg       Date:  2012-01       Impact factor: 2.345

Review 6.  Tick-borne infections in children: epidemiology, clinical manifestations, and optimal management strategies.

Authors:  Steven C Buckingham
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

7.  Fatal Rocky Mountain spotted fever in the United States, 1999-2007.

Authors:  F Scott Dahlgren; Robert C Holman; Christopher D Paddock; Laura S Callinan; Jennifer H McQuiston
Journal:  Am J Trop Med Hyg       Date:  2012-04       Impact factor: 2.345

Review 8.  Invasion of the central nervous system by intracellular bacteria.

Authors:  Douglas A Drevets; Pieter J M Leenen; Ronald A Greenfield
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 9.  Ehrlichia chaffeensis: a prototypical emerging pathogen.

Authors:  Christopher D Paddock; James E Childs
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

10.  Questions on Mediterranean spotted fever a century after its discovery.

Authors:  Clarisse Rovery; Philippe Brouqui; Didier Raoult
Journal:  Emerg Infect Dis       Date:  2008-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.